Daniel B Fried

Summary

Affiliation: University of North Carolina
Country: USA

Publications

  1. ncbi request reprint Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer
    Daniel B Fried
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, Department of Epidemiology, School of Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
    J Clin Oncol 22:4837-45. 2004
  2. ncbi request reprint Current and evolving treatment options for limited stage small cell lung cancer
    Carrie B Lee
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, 27599, USA
    Curr Opin Oncol 18:162-72. 2006
  3. ncbi request reprint Third-generation chemotherapy agents in the treatment of advanced non-small cell lung cancer: a meta-analysis
    Maria Q Baggstrom
    Division of Medical Oncology, Washington University, St Louis, Missouri 63110, USA
    J Thorac Oncol 2:845-53. 2007

Detail Information

Publications3

  1. ncbi request reprint Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer
    Daniel B Fried
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, Department of Epidemiology, School of Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
    J Clin Oncol 22:4837-45. 2004
    ..In addition, we assessed the impact of radiation fractionation and chemotherapeutic regimen on timing...
  2. ncbi request reprint Current and evolving treatment options for limited stage small cell lung cancer
    Carrie B Lee
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, 27599, USA
    Curr Opin Oncol 18:162-72. 2006
    ..Several targeted agents have also been evaluated. This review will highlight the data that have greatly impacted on the standard of limited stage small cell lung cancer care...
  3. ncbi request reprint Third-generation chemotherapy agents in the treatment of advanced non-small cell lung cancer: a meta-analysis
    Maria Q Baggstrom
    Division of Medical Oncology, Washington University, St Louis, Missouri 63110, USA
    J Thorac Oncol 2:845-53. 2007
    ..To estimate the efficacy of third-generation (3G) chemotherapy agents (paclitaxel, docetaxel, gemcitabine, vinorelbine, and irinotecan) on response and survival in stage IIIB/IV non-small cell lung cancer (NSCLC)...